Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Nevada for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Nevada only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Nevada (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Anthony Nguyen (NPI 1831317551)

Field	Value
Entity Type	Individual
Organization	Anthony Nguyen
Address	1505 Wigwam Pkwy Ste 130
City	Henderson
State	NV
ZIP	89074
Taxonomy	Hematology & Oncology Physician
NPI Enumerated	April 20, 2007

Payer Source	Total Paid
Medicare	$1.8M
Medicaid	$0

Key Findings

This provider reports $1.8M in lifetime Medicare revenue and has no Medicaid billing on file, making their commercial/payer footprint effectively single-payer (Medicare)-dominated in the available data. The absence of Medicaid billing suggests limited exposure to that payer segment and means analyses of Medicaid-facing strategy or state-level Medicaid competitiveness are not applicable for this NPI.

Revenue is highly concentrated in a small set of infused biologics: the precomputed top 3 Medicare codes account for 74.3% of total Medicare revenue, driven by J9271 ($881.4K, 50.2%), J1568 ($277.8K, 15.8%), and J0897 ($145.8K, 8.3%). This concentration indicates the practice’s financial performance is tightly tied to a few high-volume biologic therapies rather than a broadly distributed mix of office visits or low-cost procedures.

The code mix points to an infusion-centric hematology/oncology operation: very high counts of J9271 (22.6K claims, $39 avg paid/claim) combined with substantial use of J1568 (8.7K claims, $32 avg) and J0897 (8.1K claims, $18 avg) are consistent with chronic administration of oncology immunotherapy and related supportive biologics. Complementary chemotherapy administration codes (96413: 412 claims, $103 avg) and antimicrobial/supportive agents (J2506 pegfilgrastim) further support that infusions and in-office drug delivery are core services.

Competitive standing versus national Medicare peers is mixed across the top products: J9271 ranks #289 of 1841 (84th percentile) and is characterized as typical, unremarkable volume for that code at the national level; J1568 ranks #37 of 381 (91th percentile) and sits toward the top of its peer set; J0897 ranks #1555 of 10057 (84th percentile) and is also labeled typical, unremarkable. Taken together, the provider is an established, upper-quartile participant for some biologics but not a national dominant across all top therapies.

Evaluation-and-management (E/M) billing is a notable outlier for this NPI: 99215 generated $94.2K (693 claims) and ranks #810 of 145531 providers nationally (99th percentile; extreme outlier, far above typical national volume), while 99214 (666 claims, $59.9K) ranks in the 94th percentile (notably above typical national volume). This pattern indicates a heavy share of high-complexity office encounters and suggests substantial longitudinal care management and decision-making complexity within the practice.

High-volume in-office diagnostics and specimen collection support the clinical model: 85025 (2.1K claims, $17K) and 80053 (1.8K claims, $17.8K) both rank in the 97th percentile, and 36415 (2K claims, $16.4K) ranks in the 99th percentile. These elevated lab and phlebotomy volumes are consistent with frequent treatment monitoring and lab-based surveillance typical for hematology/oncology practices that manage chemotherapy, immunotherapy, and chronic supportive treatments.

Operational risk is concentrated: with J9271 alone representing $881.4K (50.2%) of Medicare revenue and the top three codes totaling 74.3% of revenue, the practice’s financial performance is sensitive to reimbursement changes, drug mix shifts, or utilization management affecting these specific biologics. The lack of Medicaid billing further concentrates payer risk onto Medicare reimbursement dynamics and may limit leverage in diversified contracting.

The provider’s NPI has been enumerated since 2007-04-20 (~19 years ago), indicating long tenure in the market. That longevity, combined with sustained high-volume infusion and complex E/M billing, suggests an established referral base and mature practice workflows centered on outpatient oncology infusion and monitoring.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

64 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J9271	Injection, pembrolizumab, 1 mg	22,600	$40	$881.4K
J1568	Injection, immune globulin, (octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg	8,680	$30	$277.8K
J0897	Injection, denosumab, 1 mg	8,100	$20	$145.8K
99215	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a high level of medical decision making, and/or the…	690	$140	$94.2K
99214	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the…	670	$90	$59.9K
J0881	Injection, darbepoetin alfa, 1 microgram (non-esrd use)	25,100	$1	$50.2K
96413	Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These…	410	$100	$42.4K
J2506	Injection, pegfilgrastim, excludes biosimilar, 0.5 mg	320	$90	$28.8K
99213	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a low level of medical decision making, and/or the…	380	$60	$24K
80053	The lab analyst performs a comprehensive metabolic panel, or CMP test in which he measures the blood level of 14 chemicals the code descriptor lists for the panel.	1,780	$10	$17.8K

Showing 1–10 of 64

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 64 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Nevada Distribution

Anthony Nguyen — 6 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Nevada

Full comparison — all codes billed, vs. state median

64 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J9271	5	40	13,000	$40	$625.8K
J1568	3	10	4,470	$30	$164.2K
J0897	10	70	3,630	$20	$94.6K
J0881	12	30	17,400	$1	$49.5K
82306	25	30	80	$30	$41.9K
J2506	2	10	270	$90	$27.8K
99233	1,070	1,150	150	$90	$26.8K
96413	12	70	210	$100	$23.7K
84443	21	80	50	$20	$22.7K
80053	5	100	160	$10	$22.2K

Showing 1–10 of 64

Related Providers

Other providers that share a Tax Identification Number (TIN) with Anthony Nguyen, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Allison Curtis Kingsley Meoz Michael & Sanchez PC	NV	Hematology & Oncology Physician	$0	$13.4M
Clark Jean	NV	Hematology & Oncology Physician	$4.2M	$21.8K
Imran Ahmed	NV	Hematology & Oncology Physician	$4M	$7.6K
Rupesh Parikh	NV	Hematology & Oncology Physician	$3.1M	$9.6K
Anuradha Thummala	NV	Hematology & Oncology Physician	$2.7M	$38.5K
Wolfram Samlowski	NV	Hematology & Oncology Physician	$2.4M	$8.1K
Ghulam Kashef	NV	Medical Oncology Physician	$2.1M	$17.1K
Robert Beer	CA	Dermatology Physician	$2M	$0
Brian Vicuna	NV	Medical Oncology Physician	$1.8M	$35.9K
Suneet Grewal	CA	Rheumatology Physician	$1.6M	$0

Nearby Providers

Other providers in the same ZIP code as Anthony Nguyen, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Rbr Management LLC	NV	Ambulance	$4.1M	$21.6M
Karen Siran-loughery Otr/l Inc.	NV	Occupational Therapist	$0	$6.4M
Independence Lifestyles Inc	NV	In Home Supportive Care Agency	$0	$4.9M
Satish K Sharma Md PC	NV	Pain Medicine Physician	$0	$4.4M
Robert Toledo Do Ltd	NV	Family Medicine Physician	$0	$3.8M
Henderson Hospital	NV	Emergency Care Clinic/Center	$0	$2.7M
Aldis Therapy Services	NV	Clinical Social Worker	$0	$2.4M
Tri-star Pediatrics Services Co	NV	Pediatrics Physician	$0	$2.1M
Nocturna Sleep Center, LLC	NV	Sleep Disorder Diagnostic Clinic/Center	$270.2K	$1.4M
Miller Hansen, PLLC	NV	Orthodontics and Dentofacial Orthopedics Dentistry	$0	$1.6M

Anthony Nguyen — Billing Profile & Reimbursement Data

Sign up for Anthony Nguyen — Billing Profile & Reimbursement Data policy alerts

Anthony Nguyen — Billing Profile & Reimbursement Data

Sign up for Anthony Nguyen — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References